The effects of propranolol on thyroxine metabolism and triiodothyronines production in man.
The effects of propranolol on the turnover of thyroxine (T4), 3,5,3'-triiodothyronine (T3), and 3,3',5'-triiodothyronine (rT3) were determined by a noncompartmental analysis in seven normal men. Fourteen normal subjects were treated with 0.2 mg T4 daily, and half of this group (seven) received in addition 80 mg propranolol daily. Fifteen days of propranolol treatment did not alter serum T4 concentration or T4 turnover. However, it lowered serum T3 concentration from 173 to 102 ng/dl (P = 0.001); T3 clearance was unchanged. Propranolol treatment elevated serum rT3 concentration from 54 to 69 ng/dl (P = 0.05); rT3 metabolic clearance rate fell from 105 to 90 liters/day but the difference did not reach statistical significance. The rT3 disposal rate was unchanged by propranolol. The fractional T4 disposal which was degraded via the deiodinative pathways was reduced from 82.0 per cent in the control subjects to 65.5 per cent in the propranolol treated subjects. Therefore, propranolol appears to be a potent inhibitor of 5'-deiodination. The interpretation of serum T3 measurements in patients treated with propranolol requires caution.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D011433:Propranolol / Q000494:pharmacology*; D013974:Thyroxine / Q000378:metabolism*; D013997:Time Factors; D014284:Triiodothyronine / Q000378:metabolism*
D001786:Blood Glucose; D014284:Triiodothyronine; D011433:Propranolol; D013974:Thyroxine